Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Nikanjam

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
International Journal of Pharmaceutics|September 9, 2006
Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiformeMina Nikanjam, Eleanor A Blakely, Kathleen A Bjornstad, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 2023
Brief Report: Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and PostpartumJeremiah D Momper, Mina Nikanjam, Brookie M Best, et al.
Journal of Pediatric Hematology/Oncology|May 18, 2018
Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California ExperienceMina Nikanjam, Aida Sun, Mark Albers, et al.
Journal of Clinical Pharmacology|December 20, 2011
Developmental pharmacokinetic changes of Lamivudine in infants and childrenAdriana H Tremoulet, Mina Nikanjam, Tim R Cressey, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2015
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosingMina Nikanjam, Clinton F Stewart, Chris H Takimoto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2021
Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and SimulationJoseph Piscitelli, Mina Nikanjam, Brookie M Best, et al.
EJNMMI Research|December 9, 2020
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patientsAmin Haghighat Jahromi, Donald A Barkauskas, Matthew Zabel, et al.
Journal of Hematology Oncology Pharmacy|March 31, 2023
Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San DiegoMina Nikanjam, Jose Tinajero, Mary McGann, et al.
Therapeutic Drug Monitoring|May 18, 2023
Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular UsersMarlon Liyanage, Mina Nikanjam, Edmund V Capparelli, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
ICOS and ICOS ligand: expression patterns and outcomes in oncology patientsMina Nikanjam, Shumei Kato, Daisuke Nishizaki, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
International Journal of Pharmaceutics|September 9, 2006
Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiformeMina Nikanjam, Eleanor A Blakely, Kathleen A Bjornstad, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 2023
Brief Report: Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and PostpartumJeremiah D Momper, Mina Nikanjam, Brookie M Best, et al.
Journal of Pediatric Hematology/Oncology|May 18, 2018
Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California ExperienceMina Nikanjam, Aida Sun, Mark Albers, et al.
Journal of Clinical Pharmacology|December 20, 2011
Developmental pharmacokinetic changes of Lamivudine in infants and childrenAdriana H Tremoulet, Mina Nikanjam, Tim R Cressey, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2015
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosingMina Nikanjam, Clinton F Stewart, Chris H Takimoto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2021
Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and SimulationJoseph Piscitelli, Mina Nikanjam, Brookie M Best, et al.
EJNMMI Research|December 9, 2020
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patientsAmin Haghighat Jahromi, Donald A Barkauskas, Matthew Zabel, et al.
Journal of Hematology Oncology Pharmacy|March 31, 2023
Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San DiegoMina Nikanjam, Jose Tinajero, Mary McGann, et al.
Therapeutic Drug Monitoring|May 18, 2023
Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular UsersMarlon Liyanage, Mina Nikanjam, Edmund V Capparelli, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
ICOS and ICOS ligand: expression patterns and outcomes in oncology patientsMina Nikanjam, Shumei Kato, Daisuke Nishizaki, et al.
Pageof 7